Company profile for Epicrispr Biotechnologies

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

​Epicrispr Biotechnologies is pioneering genetic medicine by developing therapies that dynamically control gene expression to treat complex diseases. Leveraging the power of the epigenome, the system regulating gene activity in mammalian cells. Epicrispr has created the Gene Expression Modulation System (GEMS) platform. This mix and match toolbox of epigenomic modulators enables the customization of therapies for specific di...
​Epicrispr Biotechnologies is pioneering genetic medicine by developing therapies that dynamically control gene expression to treat complex diseases. Leveraging the power of the epigenome, the system regulating gene activity in mammalian cells. Epicrispr has created the Gene Expression Modulation System (GEMS) platform. This mix and match toolbox of epigenomic modulators enables the customization of therapies for specific disease indications.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
7000 Shoreline Court, Suite 100 South San Francisco, CA 94080
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.businesswire.com/news/home/20250805959888/en/Epicrispr-Biotechnologies-Doses-First-Patient-in-First-in-Human-Clinical-Trial-of-EPI-321-for-Facioscapulohumeral-Muscular-Dystrophy

BUSINESSWIRE
05 Aug 2025

https://www.businesswire.com/news/home/20250512803482/en/Epicrispr-Biotechnologies-Named-Finalist-in-XPRIZE-Healthspan-Competition-FSHD-Bonus-Prize

BUSINESSWIRE
12 May 2025

https://www.businesswire.com/news/home/20250505956612/en/Epicrispr-Biotechnologies-Announces-Five-Presentations-Highlighting-Advances-in-Epigenetic-Modulation-and-AAV-Manufacturing-at-ASGCT-2025-Annual-Meeting

BUSINESSWIRE
05 May 2025

https://www.businesswire.com/news/home/20250423098005/en/Epicrispr-Biotechnologies-Partners-with-Springbok-Analytics-to-Integrate-AI-Muscle-Analysis-in-First-in-Human-FSHD-Study

BUSINESSWIRE
23 Apr 2025

https://www.businesswire.com/news/home/20250403888509/en/Epicrispr-Biotechnologies-Announces-FDA-Clearance-of-IND-Application-for-EPI-321-A-First-in-Class-Epigenetic-Therapy-for-FSHD

BUSINESSWIRE
03 Apr 2025

https://www.businesswire.com/news/home/20250326428705/en/Epicrispr-Biotechnologies-Secures-%2468-Million-Series-B-to-Initiate-Clinical-Trial-for-First-in-Class-Disease-Modifying-Epigenetic-Neuromuscular-Therapy-for-FSHD

BUSINESSWIRE
26 Mar 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty